Idogen AB Interim report

January–June 2019

Idogen AB (publ) Corp. Reg. No.: 556756-8521 www.idogen.com

Idogen AB Interim report

1 January – 30 June 2019

SECOND QUARTER (APRIL – JUNE 2019)

- Other operating income amounted to KSEK 1,141 (0).
- Impairment of patents totalled KSEK 4,573.
- Operating loss amounted to KSEK -11,307 (-8,689).
- Loss for the period amounted to KSEK -11,213 (-8,669).
- Cash flow from operating activities was KSEK -6,531 (-7,896).
- Loss per share before dilution was SEK -0.23 (-0.42). Loss per share after dilution was SEK -0.23 (-0.42).

PERIOD (JANUARY – JUNE 2019)

- Other operating income amounted to KSEK 1,994 (0).
- Operating loss amounted to KSEK -18,069 (-15,797).
- Loss for the period amounted to KSEK -17,865 (-15,510).
- Cash flow from operating activities was KSEK -18,562 (-3,102).
- Loss per share before dilution was SEK -0.37 (-0.75). Loss per share after dilution was SEK -0.37 (-0.75).

SIGNIFICANT EVENTS IN THE SECOND QUARTER

- In April, Idogen announced that NextCell Pharma AB had contacted the company's Board of Directors regarding a possible merger. In May, Idogen reported that discussions between the companies had been abandoned.
- In June, Idogen announced that the company had successfully developed a new patentable tolerance-inducing method to replace zebularine in the development of the company's tolerogenic cell therapy. The company has therefore written down the value of patents related to zebularine in an amount of MSEK 4.6.
- The estimate remains unchanged that our cash will last until the end of the third quarter of 2020.
- At the end of June, Idogen announced that CEO Lars Hedbys had resigned following five years as CEO of the company.

SIGNIFICANT EVENTS DURING THE PERIOD

- In January, Idogen announced that it is extending and broadening its preclinical development programme for tolerogenic cell therapy. This means the clinical trials for IDO 8 and IDO T may be delayed by six months and start in the second half of 2020 for IDO 8 and first half of 2021 for IDO T.
- In March, Idogen announced the decision to postpone plans to apply for the listing on Nasdaq First North. The company made the decision as it first wishes to conclude the evaluation of its new methods for production of Idogen's tolerogenic cell therapy.
- The change of CEO will postpone the transfer to Nasdaq First North, as there is a requirement that the company's CEO must have been employed for at least three months.
- Arctic Securities was chosen as Corporate Advisor (CA) ahead of the listing on First North.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- Anders Karlsson was appointed as the company's new CEO as of 20 August.
- No other significant events occurred after the end of the period that affected the results or financial position.

CONDENSED EARNINGS AND CASH FLOW

(Amounts in KSEK unless otherwise stated)	2019 3 months Apr-June	2018 3 months Apr-June	2019 6 months Jan-June	2018 6 months Jan-June	2018 12 months Jan-Dec
Net sales	1,141	0	1,994	0	3,766
Operating expenses	-12,448	-8,689	-20,063	-15,797	-31,627
Operating loss	-11,307	-8,689	-18,069	-15,797	-27,861
Loss for the period after net financial items	-11,213	-8,669	-17,865	-15,510	-27,634
Average number of shares	48,491,533	20,779,201	48,491,533	20,778,839	21,843,166
Average number of warrants	0	13,068,876	4,254,306	15,079,153	11,790,710
Loss per share before dilution (SEK)	-0.23	-0.42	-0.37	-0.75	-1.27
Loss per share after dilution (SEK)	-0.23	-0.42	-0.37	-0.43	-1.27
Cash flow from operating activities	-6,531	-7,896	-18,562	-3,102	-10,394
KEY FIGURES					
Working capital	29,051	16,597	29,051	16,597	42,306
Acid-test ratio (%)	306	203	306	203	305
Equity/assets ratio (%)	70	60	70	60	71
Loss per share before dilution	-0.23	-0.42	-0.37	-0.75	-1.27
Average number of shares	48,491,533	20,779,201	48,491,533	20,778,839	21,843,166

Definitions of Key Figures

Working capital

Total current assets (including cash and cash equivalents) less current liabilities.

Acid-test ratio

Total current assets (including cash and cash equivalents) relative to current liabilities.

Equity/assets ratio

Shareholders' equity in relation to balance sheet total

Earnings per share before dilution

Profit after tax divided by the average number of shares for the period.

Average number of shares

The average number of shares on the day when the new issue is registered.

CEO comment

After securing access to an improved scientific assessment method, Idogen began the year by conducting analyses of the company's existing, zebularine-based method of developing tolerogenic dendritic cells. These sophisticated analyses showed that zebularine failed to produce the tolerance-inducing effect indicated in earlier preclinical trials. The company's research team therefore immediately began extensive work to identify more appropriate substances. In June, we observed that our efforts had borne fruit – we have now established a new method that will enable the continued development of our cell therapy projects in the areas of haemophilia (IDO 8), kidney transplantation (IDO T) and autoimmune diseases (IDO AID).

The new method is based on a carefully selected combination of tolerance-inducing substances that will replace zebularine. The combination consists of a number of molecules that are essential for the production of tolerogenic dendritic cells. Independently, the substances have limited effect, but in combination they produce a very powerful effect.

A preliminary assessment of patent literature, conducted in collaboration with our patent advisor Sagittarius Intellectual Property LLC in London, suggests that the method should be patentable and does not infringe upon previously issued patents. Work has begun to apply for a patent for our new method.

Intensive work during the winter and spring has resulted in a change and fundamental improvement in our technology. When we began work to identify new tolerance-inducing substances, we expected it to take six months, but as with all exploratory projects, it is naturally impossible to know if and when the task would be fulfilled. Successfully establishing a new and improved method already after five months is a major achievement, the importance of which can hardly be overestimated, and something our researchers should be given a great deal of credit for.

With existing cash estimated to provide sufficient liquidity through the third quarter of 2020, we will now continue the development of our tolerogenic cell therapy towards the next important interim target – to initiate our first clinical trial.

Together with the Board of Directors, I believe the company – with its new technology, strong capital situation and strong team – is in a very good position. I have therefore decided to hand over the baton in a structured manner to our new CEO, Anders Karlsson, and look forward to following the company's continuing progress – albeit from a distance.

Lars Hedbys, Chief Executive Officer

Idogen in brief

Idogen (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The term "tolerogenic" refers to the immune system's selective tolerance of a specific pathogenic or immune activating antigen following treatment with Idogen's therapy. Idogen's intention is to revolutionise the treatment of several disorders in which the body's immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

WHEN THE IMMUNE SYSTEM HAS BECOME YOUR ENEMY

The ability to create a properly functioning immune system that protects and defends the body from invasion by foreign organisms – such as viruses, bacteria and tumours – would revolutionise the treatment of patients with severe chronic illness. Idogen aims to be part of this revolution. The company contributes by developing cell therapies, which is a different approach to conventional medical therapies. Instead of administering a chemical substance to the body, the patient is treated with their own cells.

Dendritic cells control other immune system cell's recognition of what is part of us (self) and what is foreign (non-self). The dendritic cells that recognise bacteria or viruses activate our immune system (red) and those that recognise the body's own cells stop the body from attacking its own tissues and create tolerance (green).

IDOGEN'S TECHNOLOGY

The technology in Idogen's therapy entails that cells from the patient's blood are treated in test tubes in a unique manner and thereby develop into tolerogenic dendritic cells. These programmed dendritic cells are then returned to the patient. In the body, tolerogenic dendritic cells have the capacity to specifically counteract harmful immune reactions and create tolerance, without influencing the rest of the immune system.

Through this technology, Idogen is developing a platform for tolerogenic cell therapy. Idogen's vision is to develop the first tolerogenic cell therapy with long-lasting effects for the treatment of patients with major unmet medical need.

In January 2019, the company announced that analyses conducted using an improved scientific assessment model indicated that the company's existing method, based on zebularine as a tolerance inducer, failed to give the effect indicated in earlier preclinical tests. A comprehensive systematic evaluation of a number of alternative tolerance inducers therefore began, aiming at identifying a more effective method to create dendritic cells that can teach the body to tolerate pharmaceuticals, the body's own molecules and cells. This work resulted in the establishment of a new method for developing the company's cell therapy projects.



Idogen's therapy entails that cells from the patient's own blood are developed outside the body into dendritic cells that specifically counteract the harmful immune reaction and create tolerance, without influencing the rest of the immune system. These programmed dendritic cells are then returned to the patient.

IDO 8 – WHEN THE BODY'S IMMUNE SYSTEM ATTACKS FACTOR VIII, A CRITICAL MEDICINE

Idogen's most advanced product candidate, IDO 8, is designed for patients with severe haemophilia A who have developed inhibitory antibodies against their critical treatment with coagulation factor VIII (FVIII). Coagulation factor VIII has no effect on these patients and there is a substantial increase in mortality and a major unmet medical need. The company has chosen haemophilia A as the first indication due to the major unmet medical need of these patients and because the disease has a well-defined antigen, which means that there are good conditions to develop a successful treatment for this patient group. The company is planning to start a first Phase I/IIa clinical trial in humans in the second half of 2020.

IDO T – WHEN THE BODY'S IMMUNE SYSTEM ATTACKS A TRANSPLANTED ORGAN

The same method that is currently under development for the treatment of haemophilia A can also be used for other indications with only minor adjustments to the production process. In transplantation, the basic principle is to "teach" the patient's immune system to recognise and accept the transplanted organ rather than to attack it. This could eventually reduce the need for current methods of often lifelong treatment with drugs that inhibit immune system functionality.

There is a major unmet need for long-acting, cost-effective and safe treatment to avoid the risk of organ rejection and reduce the impact of side effects from current immunosuppressive therapies.

Preclinical development in IDO T is ongoing with the aim of commencing a Phase I/IIa clinical trial in the first half of 2021.

IDO AID – WHEN THE BODY'S IMMUNE SYSTEM ATTACKS THE BODY'S OWN PROTEINS

In August 2018, Idogen decided to add a third therapeutic area to its project portfolio – autoimmune diseases. Patients with autoimmune diseases are often treated for long periods of time with drugs that suppress the immune system. However, the effect on the underlying condition is rarely optimal and the treatment can lead to adverse side effects. The medical need for improved therapies is therefore high. The aim of Idogen's tolerogenic cell therapy is to dramatically reduce the need for immunosuppressive drugs by a short treatment, thereby improving patient outcomes. Idogen's research unit is currently evaluating the potential of the company's technology in a group of autoimmune diseases with major unmet medical need, where a treatment could be granted orphan drug designation.

FUTURE AND STRATEGY

Idogen's intention is to enter into commercial collaboration agreements based on the clinical trial results in each project. Several large pharmaceutical companies have already shown a major interest. In recent years, a number of smaller cell therapy companies have signed commercial collaboration agreements with global pharmaceutical companies, with attractive terms.

Idogen´s vision is the first tolerogenic cell therapy with long-term effect for the treatment of patients with large unmet medical needs

Financial information

FINANCIAL PERFORMANCE FOR THE SECOND QUARTER, 1 APRIL-30 JUNE 2019

Other operating income
Other operating income for the quarter amounted to KSEK 1,141 (0) and relates to the Horizon 2020 research funding.

Operating profit/loss
Operating loss for the quarter totalled KSEK -11,309 (-8,689), a change of KSEK -2,618 compared with the year-on-year quarter. Impairment of patents had an impact of KSEK -4,573 and adjustments for EU grants yielded a positive contribution of KSEK 1,141 while good cost control reduced costs by KSEK 814.

Profit/loss for the quarter
Loss for the quarter totalled KSEK -11,213 (-8,669). Loss per share before dilution amounted to SEK -0.23 (-0.42) and loss per share after dilution to SEK -0.23 (-0.42).

Liquidity and cash flow

- Cash flow from operating activities was KSEK -6,531 (7,896).
- Cash flow from investing activities was KSEK -140 (-404).
- Cash flow from financing activities was KSEK 0 (20).
- Cash flow for the quarter was KSEK -6,671 (-8,280).
- At the end of the period, the Group's cash and cash equivalents amounted to KSEK 42,420 (31,618).

During the quarter, a tolerance-inducing replacement for zebularine was identified. This is expected to make it possible to conclude the EU project as part of Horizon 2020. Additional grants will therefore be received. The existing cash and cash equivalents will thus last at the current activity level until the end of the third quarter of 2020.

FINANCIAL PERFORMANCE FOR THE PERIOD, 1 JANUARY-30 JUNE 2019

Other operating income
Other operating income for the period amounted to KSEK 1,994 (0) and relates to the Horizon 2020 research funding.

Operating profit/loss
Operating loss for the period totalled KSEK -18,069 (-15,797), a change of KSEK -2,272 compared with the year-on-year period. Adjustments for EU grants yielded a positive contribution of KSEK 1,994 and impairment of patents had an impact of KSEK -4,573, while other costs were reduced by KSEK 307.

Profit/loss for the period
Loss for the period totalled KSEK -17,865 (-15,510). Loss per share before dilution amounted to SEK -0.37 (-0.75) and loss per share after dilution to SEK -0.37 (-0.75).

Liquidity and cash flow

- Cash flow from operating activities was KSEK -18,562 (-3,102).
- Cash flow from investing activities was KSEK -623 (-2,244).
- Cash flow from financing activities was KSEK 0 (20).
- Cash flow for the period was KSEK -19,185 (-5,326).
- At the end of the period, the Group's cash and cash equivalents amounted to KSEK 42,420 (31,618).

In 2018, an EU grant was received, which had a positive effect on cash flow from operating activities of KSEK 12,706. In the first quarter 2019, invoices relating to the rights issue in December were paid, which explains the entire decrease in accounts payable.

Financial position
At 30 June 2019, the equity/assets ratio was 70% (60) and equity amounted to KSEK 33,158 (24,398). On the same date, total assets amounted to KSEK 47,228 (40,526).

In May 2017, Idogen was granted research funding of MEUR 2.9 (just over MSEK 29) by Horizon 2020 (the EU Framework Programme for Research and Innovation) to develop the company's tolerogenic cell therapy for the treatment of anti-factor VIII neutralising antibodies in patients with severe haemophilia A. The full amount of funding will be paid out over the course of the project. During 2018, MEUR 1.5 (KSEK 15,744) had been received. Most of the remaining funds are expected to be paid out over the next 24 months. The amount received has been recognised as deferred income. Ongoing settlement is taking place at the same rate as costs are entered for the project.

Investments
Idogen's investments were at a low level during the period, with investments in patents (which were later written down by MSEK 4.6) and laboratory equipment. The investments amounted to MSEK 0.6 (2.2).

EVENTS AFTER THE BALANCE-SHEET DATE

No other significant events affecting the interim financial statements occurred after the end of the period.

CHANGE OF CEO

Lars Hedbys resigned in June after five years as CEO.

After the balance-sheet date, Anders Karlsson was appointed as the company's new CEO as of 20 August. Anders Karlsson has extensive experience from pharmaceutical and medical technology companies, including senior positions at Novartis and Olerup International. In recent years, Anders Karlsson has been CEO of Allenex AB, where he also led the merger with CareDx Inc. In his previous positions, he successfully created sales structures, repositioned companies and negotiated global collaboration and license agreements.

EMPLOYEES AND ORGANISATION

At 30 June 2019, the number of employees was ten.

Idogen's organisation comprises all of the competencies and experience required to run the company. Close collaboration has been established with a number of key consultants in patents, preclinical management, clinical trials, cell therapy, pharmaceutical development, manufacturing, documentation, quality assurance, finance and legal matters.

ANNUAL GENERAL MEETING (AGM) AND ANNUAL REPORT

The Annual General Meeting was held on 25 June 2019 in Lund, Sweden. The Board of Directors was re-elected, and comprised Agneta Edberg (Chairman), Leif G. Salford, Christina Herder and Karin Hoogendoorn. Adjustments were made to the Articles of Association increasing the maximum number of shares to 193,966,132. The Board of Directors' mandate was renewed to conduct a private placement of up to 15% of the total number of shares or 8,560,000 shares. Unchanged instructions for the Nomination Committee were adopted.

RISKS AND UNCERTAINTIES

In addition to general uncertainty related to research and development activities and delays in clinical trials, there are no known trends, uncertainties, potential claims or any other demands, commitments or events that are reasonably likely to have a material adverse effect on the company's prospects. A detailed presentation of various risks can be found in the Annual Report (pages 26–27) and in the prospectus for the rights issue in 2018 (pages 15–18).

EQUITY

Equity was mainly impacted by the issue in 2018, and by earnings during the periods. At 30 June 2019, equity amounted to MSEK 33.2 (24.4).

THE SHARE AND SUBSCRIPTION WARRANTS

The share
Loss after tax divided by the average number of shares for the period amounted to SEK -0.37 (-0.75) for the reporting period. At the end of June 2019, Idogen had approximately 2,700 shareholders. The number of shares was 48,491,533 (20,778,472).
The subscription warrant TO3 expired on 1 April. There were 8,555,883 TO3 warrants.

Name	No. of shares	Percentage of votes/capital (%)
Avanza Pension AB	3,846,690	7.9
John Fellström	3,547,277	7.3
Kronolund AB	1,142,857	2.4
Andreas Johansson	1,018,088	2.1
Leif G Salford directly and via companies	783,010	1.6
Others	38,153,611	78.7
Total	**48,491,533**	**100.0**

TO3 REDEMPTION

The subscription period for T03 ended on 1 April with no warrants exercised as the market price was just under SEK 0.6 per share and the subscription price SEK 6 per share, as adopted as part of the issue in spring 2017.

ACCOUNTING POLICIES

This interim report has been prepared in accordance with RFR 2, Accounting for Legal Entities. The report has been prepared in accordance with IAS 34, with consideration for the exceptions and additions to IFRS specified in RFR 2.

The company has no subsidiary and no consolidated financial statements are therefore given. This means IFRS-compliant financial statements are not applicable.

The accounting policies are presented in the Annual Report on pages 33–35. No changes have been made to these policies.

AUDITOR'S REVIEW

This interim report has not been audited.

ASSURANCE BY THE BOARD OF DIRECTORS

The Board of Directors and Chief Executive Officer certify that this interim report presents a true and fair view of the company's operations, financial position and results and describes the significant risks and uncertainties faced by the company.

Lund, 20 August 2019

The Board of Directors of Idogen AB

Agneta Edberg, Chairman

Christina Herder

Karin Hoogendoorn

Leif G. Salford

Lars Hedbys, Chief Executive Officer

CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

(Amounts in KSEK)	2019 3 months Apr-Jun	2018 3 months Apr-Jun	2019 6 months Jan-Jun	2018 6 months Jan-Jun	2018 12 months Jan-Dec	2017 12 months Jan-Dec
Net sales	-	-	-	-	-	-
Other operating income	1,141	0	1,992	0	3,766	0
Total income	**1,141**	**0**	**1,992**	**0**	**3,766**	**0**
Operating expenses						
Other external costs	-4,448	-6,261	-8,666	-11,447	-21,489	-16,452
Employee benefit expenses	-3,095	-2,177	-6,165	-3,913	-9,147	-4,772
Depreciation of tangible assets	-4,904	-251	-5,232	-437	-991	-75
Operating loss	**-11,307**	**-8,689**	**-18,069**	**-15,797**	**-27,861**	**-21,299**
Interest income and similar profit items	29	143	224	513	529	0
Interest expense and similar loss items	66	-122	-20	-226	-302	-23
Loss before tax	**-11,213**	**-8,669**	**-17,865**	**-15,510**	**-27,634**	**-21,322**
Tax	-	-	-	-	-	-
LOSS FOR THE PERIOD	**-11,213**	**-8,669**	**-17,865**	**-15,510**	**-27,634**	**-21,322**
OTHER COMPREHENSIVE INCOME	-	-	-	-	-	-
COMPREHENSIVE INCOME FOR THE PERIOD	**-11,213**	**-8,669**	**-17,865**	**-15,510**	**-27,634**	**-21,322**

CONDENSED STATEMENT OF FINANCIAL POSITION

(Amounts in KSEK)	30 Jun 2019	30 Jun 2018	31 Dec 2018
ASSETS			
Intangible assets			
Patents	-	3,600	4,060
Total intangible assets	**-**	**3,600**	**4,060**
Tangible assets			
Leasehold improvements	1,574	1,356	1,766
Equipment, tools, fixtures and fittings	2,532	2,845	2,890
Total tangible assets	**4,107**	**4,201**	**4,656**
Total assets		**7,801**	**8,716**
Other receivables	228	461	706
Prepaid expenses and accrued income	473	646	647
Cash and bank balances	42,421	31,618	61 605
Total current assets	**43,122**	**32,725**	**62,957**
TOTAL ASSETS	**47,228**	**40,526**	**71,674**
EQUITY			
Restricted equity			
Share capital	3,394	1,454	3,394
Fund for development expenses	2,918	2,087	2,918
Total restricted equity	**6,312**	**3,542**	**6,312**
Non-restricted equity			
Share premium reserve	36,828	42,035	36,828
Profit brought forward	7,882	-5,669	35,516
Loss for the year	-17,865	-15,510	-27,634
Total non-restricted equity	**26,846**	**20,856**	**44,710**
Total equity	**33,158**	**24,398**	**51,023**
Current liabilities			
Accounts payable – trade	2,184	2,282	7,167
Other liabilities	1,599	811	362
Accrued expenses and deferred income	10,287	13,036	13,122
Total current liabilities	**14,071**	**16,128**	**20,650**
TOTAL EQUITY AND LIABILITIES	**47,228**	**40,526**	**71,674**

CONDENSED STATEMENT OF CHANGES IN EQUITY

(Amounts in KSEK)	Share capital	Fund for development expenses	Share premium reserve	Other non-restricted equity	Profit/ loss for the year	Total equity
Opening balance at 1 Jan 2018	**1,454**	**2,087**	**42,015**	**-5,669**		**39,888**
Appropriation of profits as per AGM						
New issue	0		20			20
Capital raising expenses						
Allocation to fund for development expenses						
Loss for the period					-15,510	-15,510
Closing balance at 30 June 2018	**1,454**	**2,087**	**42,035**	**-5,669**	**-15,510**	**24,398**

(Amounts in KSEK)	Share capital	Fund for development expenses	Share premium reserve	Other non-restricted equity	Profit/ loss for the year	Total equity
Opening balance at 1 Jan 2019	**3,394**	**2,918**	**36,829**	**7,882**		**51,023**
Appropriation of profits as per AGM						
New issue						
Capital raising expenses						
Allocation to fund for development expenses						
Loss for the period					-17,865	-17,865
Closing balance at 30 June 2019	**3,394**	**2,918**	**36,829**	**7,882**	**-17,865**	**33,158**

Shareholdings disclosure	**No. of shares**
Holding/value at beginning of the year	48,491,533
Holding/value at 30 Jun 2019	48,491,533
Total no. of shares after fully subscribed issue	**48,491,533**

CONDENSED STATEMENT OF CASH FLOWS

(Amounts in KSEK)	2019 3 months Apr-Jun	2018 3 months Apr-Jun	2019 6 months Jan-Jun	2018 6 months Jan-Jun	2018 12 months Jan-Dec
OPERATING ACTIVITIES					
Operating loss before financial items	-11,307	-8,689	-18,069	-15,797	-27,861
Reversal of depreciation/amortisation	4,904	251	5,232	437	991
Interest received	29	143	224	513	529
Interest paid	66	-122	-20	-226	-302
Cash flow from operating activities	**-6,308**	**-8,418**	**-12,633**	**-15,073**	**-26,643**
Increase/Decrease in prepaid expenses and accrued income	355	-157	652	108	-108
Increase/Decrease in accounts payable	264	214	-4,983	-1,061	3,825
Increase/Decrease in other current liabilities	-842	465	-1,597	12,925	12,528
Cash flow from operating activities	**-6,531**	**-7,896**	**-18,562**	**-3,102**	**-10,393**
INVESTING ACTIVITIES					
Investment in intangible assets	-140	-132	-513	-370	-831
Investment in tangible assets	-	-266	-110	-1,874	-2,883
Cash flow from investing activities	**-140**	**-404**	**-623**	**-2,244**	**-3,714**
FINANCING ACTIVITIES					
New issue	-	20	-	20	38,769
Cash flow from financing activities	**-**	**20**	**-**	**20**	**38,769**
Cash flow for the period	-6,671	-8,280	-19,185	-5,326	24,661
Cash and cash equivalents at the beginning of the period	49,091	39,898	61,605	36,943	36,943
Cash and cash equivalents at the end of the period	**42,420**	**31,618**	**42,420**	**31,618**	**61,605**

FINANCIAL CALENDAR

Interim report January – September 2019	22 October 2019
Year-end report 2019	11 February 2020

IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT:

Agneta Edberg, Chairman of the Board
Tel: +46 (0) 705 55 75 18
E-mail: edberg.agneta@gmail.com

ADDRESS

Idogen AB
Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden

This is an English version of the original Swedish report communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This information is such that Idogen AB is obligated to publish under the EU Market Abuse Regulation (MAR) and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on 20 August 2019.